Find out more about who we are, what we do and the people behind Epitopea.
Find out what makes us unique and the work we do with our revolutionary CryptoMapTM platform.
All the latest company news, press releases and updates from Epitopea.

Our Platform

Revealing Novel Antigens to Power a New Class of Cancer Immunotherapies
Learn More

CryptoMapTM

We believe improved cancer therapies are needed to truly transform the lives of cancer patients. We are developing accessible off-the-shelf RNA cancer immunotherapies that we believe will inspire a more durable outcome for cancer patients.
Watch video
Epitopea is redefining cancer vaccine development through CryptoMap™, our proprietary discovery engine that uncovers tumor-specific antigens hidden within the dark genome—the 98% of the genome historically overlooked in oncology. These novel cryptic antigens (Cryptigens™) are directly presented on tumors, highly tumor-selective, and shared across patients, enabling scalable off-the-shelf (OTS) therapies.
We use our proprietary CryptoMapTM discovery platform to discover these hidden CryptigensTM, based on an empirically-anchored platform that leverages world-leading mass spectroscopy, immunopeptidomics, genomics, and systems bioinformatics.

Cryptigens™ are strongly immunogenic, allowing us to design multi-antigen mRNA cassettes with unprecedented potency, specificity, and coverage.

The CryptoMapTM antigen discovery platform has the potential to unlock best-in-class therapeutic opportunities across numerous indications.

Publications


Title Year Journal Authors View

Tumor antigens preferentially derive from unmutated genomic sequences in melanoma and non-small cell lung cancer

2025 Nature Anca Apavaloaei, Et al View

Breast cancer immunopeptidomes contain numerous shared tumor antigens

2024 The Journal of Clinical Investigation Eralda Kina, Et al View

Induced pluripotent stem cells display a distinct set of MHC I-associated peptides shared by human cancers

2022 Cell Reports Anca Apavaloaei, Et al View

Immunopeptidomic analyses of colorectal cancers with and without microsatellite instability

2022 MCP Online Jenna Cleyle, Et al View

Atypical acute myeloid leukemia-specific transcripts generate shared and immunogenic MHC class-I-associated epitopes

2021 Immunity: A Cell Press journal Grégory Ehx, Et al View

Proteogenomics Uncovers a Vast Repertoire of Shared Tumor-Specific Antigens in Ovarian Cancer

2020 Cancer Immunology Research Qingchuan Zhao, Et al View

Noncoding regions are the main source of targetable tumor-specific antigens

2018 Science Translational Medicine Céline M. Laumont, Et al View


Revealing Novel Targets For Next Generation Immunotherapies
© 2022 – 2026 Epitopea Ltd | All Rights Reserved
Created by FDM Digital
film-play